Key result
Activation of TLR3 in human cardiac fibroblasts strongly induced NF-κB signaling and proinflammatory cytokine secretion while significantly downregulating γ-protocadherin gene expression.
Why the study?
Building on prior findings in diseased heart tissue, the study aimed to explore the specific effects of TLR1, TLR3, and TLR7 activation on NF-κB signaling, cytokine production, and γ-protocadherin expression in cardiac fibroblasts.
TLR3 activation strongly induces inflammatory responses and reduces γ-protocadherin levels in human cardiac fibroblasts, highlighting its potential role in cardiac remodeling and as a therapeutic target.
Answers are grounded in this paper and cite their sources.
TLR3 activation may promote cardiac inflammation; hypothesis-generating for γ-protocadherin role and requires in vivo validation.
Fibroblasts play a pivotal role in key processes within the heart, particularly in cardiac remodeling that follows both ischemic and non-ischemic injury. During remodeling, fibroblasts drive fibrosis and inflammation by reorganizing the extracellular matrix and modulating the immune response, including toll-like receptor (TLR) activation, to promote tissue stabilization. Building on findings from our prior research on heart tissue from patients with advanced coronary artery disease and aortic valve disease, this study sought to explore specific effects of TLR1, TLR3, and TLR7 activation on NF-κB signaling, proinflammatory cytokine production, and γ-protocadherin expression in cardiac fibroblasts. Human cardiac fibroblasts were exposed to agonists for TLR1, TLR3, or TLR7 for 24 h, followed by an analysis of NF-κB signaling, cytokine production, and γ-protocadherin expression. The activation of these TLRs triggered distinct responses in the NF-κB signaling pathway, with TLR3 showing a stronger activation profile compared to TLR1 and TLR7, particularly in downregulating γ-protocadherin expression. These findings highlight a potential role for TLR3 in amplifying inflammatory responses and reducing γ-protocadherin levels in cardiac fibroblasts, correlating with the enhanced inflammation and lower γ-protocadherin expression observed in diseased myocardium from patients with coronary artery disease and aortic valve disease. Consequently, TLR3 represents a potential therapeutic target for modulating immune responses in cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Chaudhari et al. (2025) studied Cardiac remodeling and inflammation (in vitro). TLR1, TLR3, and TLR7 agonists (Pam3CSK4, Poly I:C, R848) vs. Vehicle (DMSO) was evaluated on NF-κB signaling pathway gene expression and γ-protocadherin expression. Activation of TLR3 in human cardiac fibroblasts strongly induced NF-κB signaling and proinflammatory cytokine secretion while significantly downregulating γ-protocadherin gene expression.
Synapse has enriched 10 related papers. Consider them for comparative context: